



Company: Founded in 2002; located in Columbia, SC, USA.

Business: Discovery and development of drugs suppressing cellular reprogramming.

Funding: close to \$17M raised, mostly through 14 competitive grants and outlicensing revenue.

Intellectual Property: Senex holds **8 issued and 8 pending US patents** covering the composition-of-matter of Senex's compounds and uses of **any** Mediator kinase inhibitors for different medical applications.

Senex's Management and Board:

Founder, President, Chief Scientific Officer, Board Chair. Igor Roninson, PhD. Endowed Chair, Director of Center for Targeted Therapeutics at the University of South Carolina. Winner of AACR Award for Meritorious Achievement in Cancer Research. Inventor of 47 issued US patents.

Chief Medical Officer. George Wilding, MD. Former Vice President and Deputy Chief Academic Officer at MD Anderson Cancer Center. Former Director of Carbone Comprehensive Cancer Center and Head of Hematology-Oncology Division at the University of Wisconsin.

Director of Research. Mengqian Chen, PhD. Inventor on several Senex's patents and Principal Investigator on Senex's NIH grants.

Head of Business Development. Karthik Gopalakrishnan, PhD.

Board members:

Bob Bonczek, JD, MBA.

Dani Bolognesi, PhD.

Richard Davidson, PhD.

A new class of drugs that prevent cancer drug resistance and metastasis, with single-agent activities in prostate and other cancers.

The Need – Improve the Outcome of Cancer Treatment

While new targeted drugs have made great strides in suppressing the growth of cancerous tumors, their effects are typically short-lived. Almost all tumors stop responding to treatments allowing the cancer to continue progressing.

In prostate cancer, principal treatments cut off access to the male hormone androgen that cancer cells need to grow, but over time, tumors adapt themselves to grow without it. As a result, leading prostate cancer treatments only prolong patients' lives by several months.

The Solution – Suppress Cellular Reprogramming

Senex has pioneered the development of a novel class of drugs that selectively target Mediator kinase (CDK8/19), the protein required for cellular reprogramming that tumors use to adapt for treatment resistance and metastatic growth.

Senex generated a pipeline of highly selective Mediator kinase inhibitors. The lead candidate is orally available, optimized for GMP synthesis, validated preclinically and well tolerated in rodents and non-human primates.

Our drugs suppress advanced prostate cancers, some breast cancers and leukemias as single agents, prevent tumor resistance to other anticancer drugs and inhibit metastatic growth.

Primary indication - Prostate Cancer: Long-term treatment of tumor-bearing animals leads to tumor shrinkage and disappearance, unprecedented in these cancers. Our drugs also suppress prostate cancer growth in the bone, the principal cause of this cancer's lethality.

Competitive Advantages: Works in prostate cancers that no longer respond to competitors' drugs. Highly selective and potent reducing the risk of toxicity. Issued patents cover the use of **any** Mediator kinase inhibitors for prostate and breast cancers. Unique preclinical and clinical experience.

Investor Exit Strategy: Clinical proof-of-concept in advanced prostate cancer in 3-4 years making us an acquisition target.

Contact: Igor Roninson, PhD, President, Senex Biotechnology, Inc.

Email: roninson@senexbio.com or info@senexbio.com Website: <https://senexbio.com>